New antibody combo aims to control hard-to-treat prostate cancer
NCT ID NCT06866548
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This early-stage trial tests whether combining two antibodies (anti-IGF-1R and anti-PD-1) can safely control metastatic castration-resistant prostate cancer (mCRPC) — a type that has stopped responding to hormone therapy. Seven men with advanced disease will receive the combination and be monitored for side effects and signs of cancer progression. The goal is to slow the cancer, not cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCRPC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can a new pill outsmart resistant prostate cancer?
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?
- Can an immune booster make hormone therapy work better against prostate cancer?
- Can a pill outsmart Tumors' defenses?
- Half the dose, same hope? trial tests cutting hormone therapy in prostate cancer